BriaCell Completes Bria-PROS+™ Clinical Supply Manufacturing, Paving Way for Prostate Cancer Trial
BCTX is trading near its 52-week low of $3.6 (14% above the low).
Summary
BriaCell Therapeutics has successfully completed the manufacturing of clinical supplies for Bria-PROS+™, its next-generation personalized immunotherapy candidate for prostate cancer. This milestone is a critical step towards initiating clinical evaluation for the program, which was supported by a $2 million non-dilutive grant from the US National Cancer Institute. The Bria-PROS+™ candidate is based on the same Bria-OTS+ platform as the company's recently FDA IND-cleared breast cancer immunotherapy candidate, Bria-BRES+, indicating a validated technology. For a clinical-stage biotech company, particularly one that recently disclosed a going concern warning, advancing a new pipeline candidate into clinical readiness is a significant positive development that could attract future investment and validate its technology platform. Investors will now watch for the company's IND filing and the subsequent initiation of clinical trials for Bria-PROS+™.
At the time of this announcement, BCTX was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.3M. The 52-week trading range was $3.60 to $37.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.